Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

6.1K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

8.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Standardisation of Imaging Surveillance for Patients With Metastatic Melanoma Stopping Immune Checkpoint Inhibitors.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
Same author

IMMEDIATE POST-ANAESTHESIA CONFUSION AND AGITATION IN ADULT SURGICAL PATIENTS: INCIDENCE AND CLINICAL CORRELATES.

Georgian medical news·2026
Same author

AEROBIC AND RESISTANCE TRAINING SHOW DIVERGENT ASSOCIATIONS WITH INSULIN SENSITIVITY AND SHORT-TERM GLYCEMIC EXPOSURE IN PREDIABETES: A CROSS-SECTIONAL STUDY.

Georgian medical news·2026
Same author

The usability of an electronic health record in a public healthcare facility in South Africa.

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde·2026
Same author

The impact of the COVID-19 pandemic on maternal mortality in a South African metropole (2020 - 2021): A retrospective cohort study.

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde·2026
Same author

Abstracts Association Tunisienne de Médecine Néonatale (ATMN).

La Tunisie medicale·2026

Related Experiment Video

Updated: Mar 11, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.3K

Targeting of BCR-ABL: Lessons learned from BCR-ABL inhibition.

X Lin1, M Z Qureshi2, R Attar3

  • 1Department of Pharmacology, Southwest Medical University, Sichuan, Luzhou 646000, China.

Cellular and Molecular Biology (Noisy-Le-Grand, France)
|November 30, 2016
PubMed
Summary

The Philadelphia chromosome, a result of a BCR-ABL fusion gene, is central to leukemia. Understanding its genetic and proteomic basis, including mutations and signaling pathways, is key to developing targeted therapies.

More Related Videos

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.8K
Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.4K

Related Experiment Videos

Last Updated: Mar 11, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.3K
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.8K
Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.4K

Area of Science:

  • Hematology
  • Molecular Biology
  • Genetics

Background:

  • The Philadelphia chromosome arises from a balanced translocation between chromosomes 9 and 22.
  • This translocation creates the BCR-ABL fusion gene, crucial in leukemia development.
  • Advances in genomics have identified key signaling pathways mutated in leukemia.

Purpose of the Study:

  • To review the biochemical characteristics of BCR-ABL+ cells.
  • To elucidate the mechanisms of mutation generation and BCR-ABL signaling crosstalk.
  • To summarize current strategies targeting BCR-ABL, including natural products.

Main Methods:

  • Review of existing literature on BCR-ABL, leukemia genetics, and proteomics.
  • Analysis of genome-wide profiling data (sequencing, microarrays).
  • Examination of miRNA regulation and therapeutic targeting strategies.

Main Results:

  • Detailed biochemical profiles of BCR-ABL+ cells.
  • Insights into mutation generation and signaling pathway interactions.
  • Overview of miRNA-mediated regulation and natural product-based therapies.

Conclusions:

  • Understanding the BCR-ABL protein network is vital for leukemia research.
  • Targeting BCR-ABL pathways offers therapeutic potential.
  • This knowledge advances the development of personalized medicine for leukemia patients.